Most Read Articles
Roshini Claire Anthony, 09 Nov 2018

Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.

28 Sep 2018
In Malaysia, hidradenitis suppurativa has a male preponderance, occurring at an early age with greater disease severity, as reported in a recent study.
Audrey Abella, 22 Oct 2018
Consumption of any dairy (eg, milk, yogurt, and cheese) regardless of amount or frequency was associated with an increased risk for acne compared with no dairy intake in children, adolescents, and young adults, a meta-analysis has shown.
15 Oct 2018
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Superficial chemical peels relatively safe for darker skins

30 Aug 2018

Superficial chemical peel treatments are safe for darker skins, yielding relatively low complication rates, a recent study has shown. However, those with skin type VI are at higher risk of adverse events.

Researchers performed a retrospective analysis of 473 chemical peel treatments performed on 132 patients (mean age 40.3±10.9 years), whose skin types ranged from type III to type VI. Each patient received a mean of 3.5 peels, though most of the treatments were performed on females (388 vs 85).

Eighteen treatments (3.8 percent) resulted in either short-term (1.1 percent) or long-term (2.7 percent) side effects. The median duration of the side effects was 4.5 weeks and the most common complications were prolonged crust (2.3 percent) and erythema (1.9 percent).

Side effects were most commonly observed in those with skin type IV (5.4 percent), type III (2.7 percent) and type VI (12.5 percent).

Relative to skin type III, those with type VI were at significantly higher risks of side effects (odds ratio [OR], 5.14; 95 percent CI, 1.21–21.8; p=0.0118), while those with skin type V demonstrated a nonsignificantly lower risk (OR, 0.67; 0.15–3.05; p=0.0659).

Side effects were most frequent in single peels (4.7 percent), treatments that used glycolic acid (6.03 percent) and in patients who had previously received chemical peels. On the other hand, peels performed in the winter had a nonsignificantly lower likelihood of resulting in side effects than those performed in the spring (OR, 0.13 0.02–1.02; p=0.078).

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Nov 2018

Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.

28 Sep 2018
In Malaysia, hidradenitis suppurativa has a male preponderance, occurring at an early age with greater disease severity, as reported in a recent study.
Audrey Abella, 22 Oct 2018
Consumption of any dairy (eg, milk, yogurt, and cheese) regardless of amount or frequency was associated with an increased risk for acne compared with no dairy intake in children, adolescents, and young adults, a meta-analysis has shown.
15 Oct 2018
New drug applications approved by US FDA as of 1 - 15 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.